Claims
- 1. A method of treating or preventing obesity in a human subject comprising administering to said subject an effective amount of an amylin or an amylin agonist.
- 2. A method according to claim 1 wherein said amylin agonist is an amylin agonist analogue.
- 3. A method according to claim 2 wherein said amylin agonist analogue is 25,28,29Pro-h-amylin.
- 4. A method according to claim 1 wherein said amylin or amylin agonist is administered subcutaneously.
- 5. A method according to claim 4 wherein said amylin or amylin agonist is administered from 1 to 4 times per day.
- 6. A method according to claim 5 wherein said amylin or amylin agonist is administered in an amount from 30 μg per dose to 300 μg/dose.
- 7. A method according to claim 6 wherein said amylin or amylin agonist is administered three times per day in an amount of about 60 μg per dose.
- 8. A method according to claim 6 wherein said amylin or amylin agonist is administered four times per day in an amount of about 60 μg per dose.
- 9. A method according to claim 7 or claim 8 wherein an amylin agonist is administered.
- 10. A method according to claim 9 wherein said amylin agonist is 25,26,29Pro-h-amylin.
- 11. A method of reducing insulin-induced weight gain in a human subject taking insulin comprising administering to said subject an effective amount of an amylin or an amylin agonist.
- 12. A method according to claim 11 wherein an amylin agonist is administered.
- 13. A method according to claim 11 wherein said amylin agonist is 25,28,29Pro-h-amylin.
- 14. A method according to claim 11 wherein said subject has diabetes mellitus.
- 15. A method according to claim 14 wherein said subject has type 1 diabetes mellitus.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 08/870,762, filed Jun. 6, 1997, the contents of which is hereby incorporated by reference in its entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US98/11753 |
6/5/1998 |
WO |
|